| Literature DB >> 27264183 |
Carlos G Briseño1, Malay Haldar2, Nicole M Kretzer1, Xiaodi Wu1, Derek J Theisen1, Wumesh Kc1, Vivek Durai1, Gary E Grajales-Reyes1, Arifumi Iwata1, Prachi Bagadia1, Theresa L Murphy1, Kenneth M Murphy3.
Abstract
Both classical DCs (cDCs) and monocyte-derived DCs (Mo-DCs) are capable of cross-priming CD8(+) T cells in response to cell-associated antigens. We found that Ly-6C(hi)TREML4(-) monocytes can differentiate into Zbtb46(+) Mo-DCs in response to granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) but that Ly-6C(hi)TREML4(+) monocytes were committed to differentiate into Ly-6C(lo)TREML4(+) monocytes. Differentiation of Zbtb46(+) Mo-DCs capable of efficient cross-priming required both GM-CSF and IL-4 and was accompanied by the induction of Batf3 and Irf4. However, monocytes require IRF4, but not BATF3, to differentiate into Zbtb46(+) Mo-DCs capable of cross-priming CD8(+) T cells. Instead, Irf4(-/-) monocytes differentiate into macrophages in response to GM-CSF and IL-4. Thus, cDCs and Mo-DCs require distinct transcriptional programs of differentiation in acquiring the capacity to prime CD8(+) T cells. These differences may be of consideration in the use of therapeutic DC vaccines based on Mo-DCs.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27264183 PMCID： PMC4941620 DOI： 10.1016/j.celrep.2016.05.025
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423